Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) announced its quarterly earnings data on Wednesday. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. Here are the key takeaways from Mirum Pharmaceuticals’ conference call:Get Mirum Pharmaceuticals alerts:Strong commercial performance: Second-quarter net product sales rose to $176 million, up from $128 million a year earlier, driven by LIVMARLI and the bile acid medicines. Mirum Pharmaceuticals has a 12 month low of $50.25 and a 12 month high of $130.00. Featured StoriesReceive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.